默沙东九价HPV疫苗在华获批男性适应证 适用于16至26岁男性接种

每日经济新闻
14 Apr

4月14日,默沙东宣布,佳达修9(以下简称“九价HPV疫苗”)多项新适应证已获得国家药品监督管理局的上市批准,适用于16至26岁男性接种。这一获批使佳达修9成为中国境内首个且目前唯一获批、可适用于适龄男性女性接种的九价HPV疫苗。  这也是继今年1月默沙东四价HPV疫苗获批用于男性接种后,默沙东在九价HPV疫苗男性适应证方面的突破。  相较四价疫苗,九价疫苗可为接种者提供更多HPV型别的防护。针对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10